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cAtherosclerotic cardiovascular disease, including
myocardial infarction and stroke, remains the most
common cause of death and disability in the devel-
oped world. The primary driver for development of
the disease is inflammation (1); in atherosclerosis,
this is primarily due to macrophage infiltration of
the vascular intima. Positron emission tomography
(PET) imaging with the metabolic tracer 18F-
fluorodeoxyglucose (18F-FDG) is a highly sensitive,
See page 1294
noninvasive technique that can give a readout of
vascular glucose metabolism, believed to be a sur-
rogate of atherosclerotic plaque inflammation (2).
Glucose uptake by macrophages is significantly
higher than in other plaque cells (3,4). Macro-
phages can also metabolize fatty acids, but in the
anaerobic environment of the plaque, they prefer-
entially use glucose because this does not require
oxygen to produce adenosine triphosphate (5,6).
Studies in humans with atherosclerosis have dem-
onstrated that the degree of vascular 18F-FDG
uptake relates to the presence of recent plaque
destabilization (7,8), cardiovascular risk factors
(9,10), and high-risk plaque morphology (11). It
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.
From the †Department of Medicine, Endocrinology, Diabetes and Bone
Disease, Mount Sinai School of Medicine, New York, New York;
‡Division of Cardiovascular Medicine, University of Cambridge, Cam-
bridge, United Kingdom; §Translational and Molecular Imaging Insti-
tute, Mount Sinai School of Medicine, New York, New York; Depart-
ment of Radiology, Mount Sinai School of Medicine, New York, New
York; and the ¶Department of Cardiology, Zena and Michael A. Weiner
Cardiovascular Institute and Marie-Josée and Henry R. Kravis Cardio-
vascular Health Center, Mount Sinai School of Medicine, New York,
New York. Dr. Buettner is supported in part by NIH DK0836558, Dr.
Rudd by the NIHR Cambridge Biomedical Research Centre, and Dr.
Fayad is supported in part by NIH/NHLBI R01 HL071021 and R01r
HL078667. All authors have reported that they have no relationships
relevant to the contents of this paper to disclose.as also been possible to test the efficacy of anti-
therosclerotic drugs (12) by measuring the changes
hat they cause to the 18F-FDG signal. Pre-clinical
tudies in animal models of atherosclerosis (without
iabetes) have largely confirmed that the basis of
he signal is inflammation (13), but not consistently
o (14). This is not surprising when we consider
hat all cells metabolizing glucose accumulate 18F-
DG. Plaque 18F-FDG uptake in nondiabetic in-
ividuals is therefore a useful marker of enhanced
lucose metabolism, correlating with inflammation,
ut not specific for it (15). Hypoxia also seems to
ncrease the degree to which inflammatory cells
ccumulate 18F-FDG (16).
The noninvasive readout of inflammation in
atients with type 2 diabetes mellitus (DM2) is
specially attractive because they are at higher risk
f vascular events than those without DM2. DM2
s a complex disease. Although its hallmark is
yperglycemia and impaired glucose metabolism,
qually important are disturbances in lipid metab-
lism. Both glucose and lipid levels in plasma can
till be normal in early forms of DM2, even when
he metabolism of glucose and lipid is already
everely impaired. This becomes obvious only when
tudied by either dynamic testing (for example, by a
lucose tolerance or lipid clearance test) or, better
et, through flux studies using metabolic tracers.
he second core feature of DM2 is insulin resis-
ance, defined as the inability of insulin to regulate
lucose and lipid metabolism. Insulin is the princi-
al regulator of glucose and lipid metabolism, and
herefore disturbances in glucose and lipid metab-
lism are intimately linked with insulin resistance in
M2. With the drugs that we have at our disposal,
t is easier to correct hyperglycemia than to improve
nsulin resistance. It is therefore of fundamental
mportance to differentiate the effects of hypergly-
emia (i.e., glucose toxicity) from the role of insulin
esistance in atherosclerosis.
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1303With regard to atherosclerosis, the question re-
mains whether PET imaging with 18F-FDG can
ccurately detect plaque inflammation in subjects with
M2 or animal models of DM2. It is also unclear
ow insulin resistance per se affects 18F-FDG uptake
in macrophages, cells that do express the insulin
receptor (17), but not the insulin responsive GLUT4
glucose transporter (18). It is also important to re-
member that because 18F-FDG is a glucose analog
whose uptake is competitively inhibited by increasing
blood glucose concentration (19,20), it is unknown
whether vascular 18F-FDG uptake is affected by hy-
perglycemia at the time of imaging.
The only study to explore these questions, at least in
humans, was undertaken by Kim et al. (21), who
demonstrated increasing levels of 18F-FDG uptake
ithin the carotid arteries of control subjects, through
hose with impaired glucose tolerance to frank DM2.
ecause the uptake of 18F-FDG into cells is compet-
tive with glucose, the authors were careful to ensure
hat the fasting glucose level at the time of imaging
as within normal limits. Although this study is
ncouraging, the ability to perform 18F-FDG PET
imaging in an animal model of DM2, where the
underlying pathology can be probed in a controlled
way, has not been tested.
In this issue of iJACC, Silvola et al. (22) investi-
gated the effect of mouse age and the duration of
high-fat diet on 18F-FDG uptake in 2 models of
murine atherosclerosis and compared with controls.
The novelty of this work is the use of a mouse
model in which insulin-like growth factor II (IGF-
II) is overexpressed in beta cells using the rat insulin
promoter on a LDLR/ApoB100/100 background.
LDLR/ApoB100/100 mice are the “nondiabetic”
controls, a strain that is commonly used to model human
atherosclerosis in mice. The authors had shown in a
previous study that IGF-II/LDLR/ApoB100/100 mice
are characterized by glucose intolerance, increased fasting
glycemia, and insulin resistance when compared with
LDLR/ApoB100/100 mice (23). This mimics early
DM2, but it is also important to point out that these
mice do not differ much in terms of hyperglycemia
from controls when fed the same diet. Why these
mice are insulin resistant remains somewhat un-
clear. Insulin resistance is primarily due to a failure
of insulin to suppress hepatic glucose production
and/or to increase glucose uptake into muscle and
adipose tissue. In the IGF-II/LDLR/ApoB100/100
mice, it may be that initial oversecretion of insulin
from beta cells generates chronic hyperinsulinemia
that begets insulin action. An alternative explana-
tion for the insulin-resistant phenotype may lie in wthe experimental approach chosen to overexpress
IGF2, which is under the control of the rat insulin
promoter. It has been realized in recent years that
the rat insulin promoter is not only turned on in
beta cells, but also in the hypothalamus where
insulin is expressed during development (24). Hy-
pothalamic overexpression of IGF-II may impair
hypothalamic control of whole-body insulin action
through autonomic dysregulation that can lead to
systemic insulin resistance. Although this model
may appear somewhat obscure, hyperinsulinemia
(25) and hypothalamic dysfunction (26) are now
believed to play important roles in the pathogenesis
of DM2 in humans, and therefore this model is
clinically relevant.
Probably the 2 most important factors contrib-
uting to DM2 in humans are excessive caloric
intake and aging. Both represent metabolic stressors
that worsen insulin resistance and unveil a diabetic
phenotype, which is true in humans and rodents.
Thus, the authors examined the impact of
high-fat feeding and aging on plaque size, mac-
rophage density, and uptake of 18F-FDG. They
found no differences between the 2 models regard-
ing plaque development and cellular composition,
despite the development of diabetes by a high-fat
diet. They demonstrated that the “sweet spot” for
using 18F-FDG PET to image vascular inflamma-
tion in both models was found in mice at least 6
months old and after 3 to 4 months of high-fat
feeding. Interestingly, aging decreased plaque mac-
rophage density (previously demonstrated by Rong
et al. [27] in apoE/ mice), although plaque size
itself increased and calcification was predominant
with subsequent low 18F-FDG signal, which is
likely due to impaired macrophage function and
metabolism in aging.
There are several limitations of the current study.
Although lipid levels of IGF-II/LDLR/ApoB100/100
mice did not differ from LDLR/ApoB100/100 con-
trols, as pointed out previously, this does not mean
that lipid metabolism is not altered in these mice
and thus the role of altered lipid flux on 18F-FDG
ptake remains unclear. Further, the authors did
ot examine the impact of hyperglycemia on 18F-
FDG uptake because the 2 mice models did not, at
least clinically significantly, differ in terms of glyce-
mia when fed the same diet. Another issue is that
females and males were not matched between
groups. Sex has a marked effect on high-fat feeding–
induced insulin resistance and metabolic derangement.
For example, the IGF-II/LDLR/ApoB100/100 miceere predominantly females while the controls were
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1304mostly males which introduces a significant bias
because females are often protected from high-fat
feeding–induced insulin resistance (28).
Nevertheless, the current study represents an im-
portant first step in validating 18F-FDG PET imag-
ng for the study of atherosclerosis in models of DM2.
ltimately, studies like these will allow us to dissect
he role of specific components of DM2, such asVascular inflammation evaluated by
[18F]-fluorodeoxyglucose positron
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Effects of insulin and
FDG uptake in expeontributors to the increased cardiovascular risk in
iabetes and the metabolic syndrome.
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